List view / Grid view
30 October 2015 | By Victoria White
Dr Hervé Dombret says the 'announcement brings hope to patients with AML, particularly the elderly and more frail patients who cannot undergo intensive therapies'...
20 October 2015 | By Victoria White
In the trial, a significantly greater proportion of patients on Ozanimod achieved or maintained clinical remission at 32 weeks compared with those on placebo...
25 September 2015 | By Victoria White
The CHMP adopted a positive opinion for an expanded indication of azacitidine for the treatment of adult patients aged 65 years or older with acute myeloid leukaemia who are not eligible for haematopoietic stem cell transplantation...
3 September 2015 | By Victoria White
NICE has published final draft guidance which does not recommend apremilast, saying that there is not enough evidence to demonstrate apremilast slows progression of psoriatic arthritis...
28 August 2015 | By Victoria White
Celgene has completed its acquisition of Receptos, significantly enhancing Celgene’s Inflammation & Immunology pipeline with the addition of Ozanimod...
15 July 2015 | By Victoria White
Celgene and Receptos have signed a definitive agreement in which Celgene has agreed to acquire Receptos for approximately $7.2 billion...
15 June 2015 | By Victoria White
Analyses of Celgene’s MCL-002 study, comparing Revlimid with investigators' choice in MCL, were presented at the European Haematology Association congress...
12 June 2015 | By
Celgene International has announced updated results of its pivotal Phase III FIRST trial of REVLIMID at the European Haematology Association annual congress...
19 May 2015 | By Victoria White
A post-hoc subgroup analysis of a Phase II trial of Celgene’s GED-0301 in patients with active Crohn's disease was presented at Digestive Disease Week...
18 May 2015 | By Victoria White
The FDA has granted Fast Track designations to luspatercept for two separate indications for the treatment of patients with beta-thalassemia...
16 April 2015 | By Victoria White
Results from a multicentre, randomized, placebo-controlled phase II trial (BCT-001) of apremilast in patients with Behçet's disease have been published...
19 March 2015 | By Victoria
Celgene Corporation announce results from a phase II trial of GED-0301 on patients with active Crohn's Disease have been published...
19 January 2015 | By Celgene
An oral therapy for moderate-to-severe chronic plaque psoriasis and active psoriatic arthritis, with no drug-specific pre-screening or laboratory monitoring requirements...
24 November 2014 | By Celgene International Sàrl
Celgene receives positive CHMP opinion for OTEZLA® (apremilast), the first oral PDE4 inhibitor for the treatment of patients with psoriasis and psoriatic arthritis...
3 October 2013 | By Celgene
Psoriasis of the scalp, another difficult-to-treat area, was also improved by treatment with apremilast 30 mg BID...
